Our look is new. Our purpose is the same. Learn more about our brand evolution.
The journal Neuromuscular Disease has published a summary of the FSHD Society’s 2023 scientific conference held in Milan, Italy, this past June. The article was co-authored by Jamshid Arjomand, PhD, […]
[…] tolerability with over 200 infusions totaling 46.2 patient-years of exposure.” What does this mean for FSHD? The company is developing a similar drug, AOC 1020, for FSH muscular dystrophy, which […]
[…] are the second most common cause of injury leading to death. For a person with FSHD, falling and breaking a bone may be the incident that leads to becoming reliant […]
[…] his sister, to raise awareness of FSH muscular dystrophy. Spencer says his sister’s experience with FSHD has made her who she is; organized, motivated, a force for change and a […]
[…] leading to study drug discontinuation were reported through 96 weeks of dosing,” Fulcrum noted. “Every FSHD patient faces relentless and accumulating muscle and functional loss. These long-term data further demonstrate […]
